Clinical benefit of paclitaxel/carboplatin plus bevacizumab with zoledronic acid in pulmonary epithelioid hemangioendothelioma complicated by hypertrophic pulmonary osteoarthropathy and cardiac tamponade: a case report - Scorecard - MDSpire

Clinical benefit of paclitaxel/carboplatin plus bevacizumab with zoledronic acid in pulmonary epithelioid hemangioendothelioma complicated by hypertrophic pulmonary osteoarthropathy and cardiac tamponade: a case report

  • By

  • Saki Tsuchimochi

  • Hiromichi Nakajima

  • Yukako Hattori

  • Shioto Oda

  • Hiroki Imada

  • Tetsuro Taki

  • Anna Matsuoka

  • Shogo Watanabe

  • Akira Hirota

  • Mai Shimura

  • Misao Fukuda

  • Chikako Funasaka

  • Kenichi Harano

  • Nobuaki Matsubara

  • Yoichi Naito

  • Ako Hosono

  • Genichiro Ishii

  • Toru Mukohara

  • June 2, 2026

  • 0 min

Share

Clinical Scorecard: Efficacy of Paclitaxel/Carboplatin Combined with Bevacizumab and Zoledronic Acid in Treating Pulmonary Epithelioid Hemangioendothelioma with Hypertrophic Pulmonary Osteoarthropathy and Cardiac Tamponade: A Case Study

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target PopulationPatients with advanced PEH and associated conditions such as hypertrophic pulmonary osteoarthropathy, specifically including age and clinical status.
Care Setting

Key Highlights

  • highlight

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

      • F
      • o
      • l
      • l
      • o
      • w
      • -
      • u
      • p
      • i
      • m
      • a
      • g
      • i
      • n
      • g
      • i
      • s
      • r
      • e
      • c
      • o
      • m
      • m
      • e
      • n
      • d
      • e
      • d
      • t
      • o
      • a
      • s
      • s
      • e
      • s
      • s
      • t
      • r
      • e
      • a
      • t
      • m
      • e
      • n
      • t
      • r
      • e
      • s
      • p
      • o
      • n
      • s
      • e
      • ,
      • s
      • p
      • e
      • c
      • i
      • f
      • y
      • i
      • m
      • a
      • g
      • i
      • n
      • g
      • t
      • e
      • c
      • h
      • n
      • i
      • q
      • u
      • e
      • s
      • .

      Risks

        Patient & Prescribing Data

        Include rationale for treatment choices and expected outcomes.

        Clinical Best Practices

        • best_practice

        Related Resources & Content

        Original Source(s)

        Clinical benefit of paclitaxel/carboplatin plus bevacizumab with zoledronic acid in pulmonary epithelioid hemangioendothelioma complicated by hypertrophic pulmonary osteoarthropathy and cardiac tamponade: a case report

        • by Saki Tsuchimochi, Hiromichi Nakajima, Yukako Hattori, Shioto Oda, Hiroki Imada, Tetsuro Taki, Anna Matsuoka, Shogo Watanabe, Akira Hirota, Mai Shimura, Misao Fukuda, Chikako Funasaka, Kenichi Harano, Nobuaki Matsubara, Yoichi Naito, Ako Hosono, Genichiro Ishii, Toru Mukohara

        • June 2, 2026

        Related Content

        Biology of p53 protein isoforms and their significance in hematological malignancies

        Current status and trends of immune-related adverse events in lung cancer treated with immune checkpoint inhibitors: a bibliometric analysis of the past decade (2016–2025)

        Signals of inequity in the care pathway: rural lab diagnosis, systemic therapy delays, and RAS mutation differences in metastatic colorectal cancer